Reliable Signal. Confident Decisions. Smarter Care.
An innovative medical device for a better monitoring of arterial blood pressure in intensive-care units (ICU)
- TRL 6–7
- International patents
- Peer-reviewed publication [1]
- Seamless integration with advanced AI-ready monitoring ecosystems
Normal Signal
Optimal waveform quality
Distorted Signal
Waveform alteration detected
Huge distorted Signal
Significant waveform distortion detected
False Alarms & Distorted Waveforms : A Hidden Risk
Hydraulic Chain
- Arterial catheter
- Tubing
- Transducer
- Monitor
Causes
- Air bubbles
- Clots
- Under/over damping
- Resonance artifacts
- Manual fast-flush limitations
Impact
- False alarms
- Alarm fatigue
- Misleading therapy decisions
- AI blind spot
No existing device provides continuous automatic waveform-quality monitoring.
Continuous, Automated Signal Integrity Control
CATARSI continuously evaluates the dynamic response of the invasive arterial waveform and classifies signal quality in real time — without generating additional audible alarms.
Reliable Signal
Optimal dynamic response. Hemodynamic indices (CO, SVV, PPV) fully reliable.
Signal Degradation Detected
Early waveform alteration detected. Derived indices may be affected.
Reliable Signal
Significant distortion detected. Hemodynamic parameters are compromised.
Seamless Integration
- Compact in-line add-on
- No protocol modification
- Compatible with all hydraulic tubing types
- Continuous transmission quality monitoring
Securing the Entire Measurement Chain
Clinical & Economic Impact
Better Signal
Waveform Quality
Better Decisions
Therapy Confidence
Faster Stabilization
Patient Recovery
Shorter ICU Stays
Economic Impact
Cost Savings
-
Alarm fatigue reduction
Fewer unnecessary interventions, improved staff efficiency -
Reduced false-positive alerts
Minimized diagnostic waste and therapy adjustments -
Improved resource allocation
Better prioritization of critical cases -
Reduced ICU Length of Stay[*]
Lower hospitalization costs and improved bed turnover
Patient Safety
-
Prevent misdiagnosis
Avoid therapies based on distorted signals -
Real-time validation
Continuous quality assurance throughout care -
Enhanced AI reliability
Trustworthy inputs for predictive algorithms -
Faster Stabilization
Accelerated patient recovery and better outcomes
[*] Pinsky M.R. et al. Effective hemodynamic monitoring. Crit Care 26, 294 (2022). https://doi.org/10.1186/s13054-022-04173-z
AI is Transforming Monitoring — Signal Quality Must Follow
Market
- ~150,000 ICU beds worldwide
- ~20M patients/year with invasive arterial monitoring
Industry Movement
- AI-enabled monitoring platforms
- Consolidation among global MedTech leaders
Blind Spot
- Upstream signal distortion not addressed
- Manual fast-flush remains episodic and operator-dependent
Artificial Intelligence will increasingly rely on physiological signals to support clinical decision-making. Ensuring the integrity of these signals is therefore essential.
Technology & IP Readiness
Proven technology with robust intellectual property protection and regulatory pathway clarity.
TRL 6–7
Functional industrial pre-series extensively validated in relevant clinical context (1000 hours on our virtual patient bench, digital twin).
International Patent Portfolio
Protected in key markets
Regulatory Pathway
Clinical validation and CE Mark preparation underway for European regulatory approval.
Scientific & Clinical Context
CATARSI relevance is proved by a growing body of peer-reviewed literature.
These publications highlight the clinical importance of arterial waveform quality and the limitations of current manual assessment methods.
[1] Lavault et al. Real-Time Accuracy Evaluation of Arterial Catheter Transducer Systems. IRBM, Volume 46, Issue 1, 2025, 100867, ISSN 1959-0318. https://doi.org/10.1016/j.irbm.2024.100867
[2] Saugel, B., Annecke, T., Bein, B. et al. Intraoperative haemodynamic monitoring and management of adults having non-cardiac surgery: Guidelines of the German Society of Anaesthesiology and Intensive Care Medicine in collaboration with the German Association of the Scientific Medical Societies. J Clin Monit Comput 38, 945–959 (2024). https://doi.org/10.1007/s10877-024-01132-7
[3] Saugel, B., Kouz, K., Meidert, A. et al. How to measure blood pressure using an arterial catheter: a systematic 5-step approach. Crit Care 24, 172 (2020). https://doi.org/10.1186/s13054-020-02859-w
[4] Kouz, K., Thiele, R., Michard, F. et al. Haemodynamic monitoring during noncardiac surgery: past, present, and future. J Clin Monit Comput 38, 565–580 (2024). https://doi.org/10.1007/s10877-024-01161-2
[5] Flick, Moritz; Joosten, Alexandre; Scheeren, Thomas W.L.; Duranteau, Jacques; Saugel, Bernd. Haemodynamic monitoring and management in patients having noncardiac surgery: A survey among members of the European Society of Anaesthesiology and Intensive Care. European Journal of Anaesthesiology and Intensive Care 2(1):p e0017, February 2023. https://doi.org/10.1097/EA9.0000000000000017
CATARSI and Artificial Intelligence in Hemodynamic Monitoring
AI opens very interesting future opportunities in hemodynamic assessment (false alarms reduction, use of hemodynamic variables derived from pulse contour, AI-driven closed-loop system for automatic administration of hemodynamic therapy).
CATARSI secures and improves the accuracy of input data for AI and enhances the power of algorithms by supplying a signal quality index on a major input.
[6] Michard F, Mulder MP, Gonzalez F, Sanfilippo F. AI for the hemodynamic assessment of critically ill and surgical patients: focus on clinical applications. Ann Intensive Care. 2025 Feb 24;15(1):26. https://doi.org/10.1186/s13613-025-01448-w
[7] Myatra SN, Jagiasi BG, Singh NP, Divatia JV. Role of artificial intelligence in haemodynamic monitoring. Indian J Anaesth. 2024 Jan;68(1):93-99. https://doi.org/10.4103/ija.ija_1260_23
About Us
AII Medical is a medical technology company based in Grenoble, France, dedicated to build help tools to therapeutic decision making in intensive care and anesthesia units. The company combines clinically driven engineering with deep expertise in signal quality to help healthcare teams confidently rely on the data guiding high-stakes decisions.
CATARSI is AII Medical’s flagship innovation, designed to continuously assess arterial waveform quality and secure hemodynamic signal integrity in real time across the monitoring chain.
Signal Integrity Expertise
Advanced signal processing for critical care environments
Clinically Driven Development
Designed in close collaboration with critical care teams and cardio-respiratory physiology researchers
MedTech Vision
Targeted for international deployment and hemodynamic monitoring ecosystem integration
Team & Ecosystem
A multidisciplinary team combining engineering skills with medical device expertise and clinical insights.
Core Team
Leadership
Yves Lavault
CEO
Carole Lavault
R&D Manager
Sylvain Fournier
R&D Technician
Jacqueline Lavault
Administration
Advisors & Extended Team
Daniel Anglade
Clinical Advisor
Norbert Noury
Scientific Advisor
François Boucher
Scientific Advisor
Lionel Charpentié
Innovation Advisor
Enwar Mihoub
Business Developer
Bring Signal Integrity to Your Clinical Practice
CATARSI is ready for clinical validation and market entry. Partner with us to secure hemodynamic monitoring for the AI-driven future of critical care.
- TRL 6–7 technology ready for deployment
- International patent protection
- Seamless integration with advanced AI-ready monitoring ecosystems
CATARSI Device
Ready for Clinical Deployment